Previous 10 | Next 10 |
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2022 financial result...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stocks are showing signs of life in 2023. And if you have a tolerance for risk and are willing to look for stocks to trade, the small-cap sector is one area to find stocks to watch. Historically, small-cap stocks t...
– Phase 1 trial showed 30% CR rate among 20 NPM1-mutant AML patients treated at recommended Phase 2 dose – – Phase 2 registration-directed trial expected to enroll 85 patients in the U.S. and Europe – SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology...
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the virtual SVB Securities Global Biopharma Confe...
Summary Kura Oncology, Inc. has two assets, and both produced decent data. Each asset has its own set of problems. Kura Oncology is set for cash. I covered Kura Oncology, Inc. ( KURA ) two years ago, when I said that, although I like the company’s science, p...
Cancer-focused biotech Kura Oncology ( NASDAQ: KURA ) announced Tuesday the FDA clearance of its Investigational New Drug (IND) application for solid tumor candidate KO-2806. The company expects to start the first-in-human study for KO-2806 as a Phase 1 trial in Q3 2023 to test its ef...
SAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the In...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Kura Oncology ( NASDAQ: KURA ) fell ~14% on Monday after the clinical-stage biotech announced updated data from a Phase 1/2 trial for lead asset ziftomenib in patients with relapsed/refractory acute myeloid leukemia (AML) Meanwhile, Kura’s rival for menin-targeting cancer t...
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML – – Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg – – 600 mg determined as recommended Phas...
News, Short Squeeze, Breakout and More Instantly...
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- ...
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing...
2024-05-08 08:30:00 ET Growth stocks have resoundingly outperformed value and dividend stocks since the 2008 financial crisis. While this trend is a reversal relative to historical norms, growth stocks are likely to continue to deliver outstanding returns over the long term due to the emerg...